Drugs / MART-1a peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00470015 | Mar 2007 → Apr 2009 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1a peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00470015 ↗ |
| Modality | Peptide | “Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin)” NCT00470015 ↗ |